Cancer genetics and the cardiotoxicity of the therapeutics

Journal of the American College of Cardiology

Volumn 61, Issue 3, 2013, Pages 267-274

  Lal, Hind ^a   Kolaja, Kyle L ^b   Force, Thomas ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

cardio oncology; cardiotoxicity; kinase inhibitors

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TROPONIN I;

CANCER GENE THERAPY; CANCER GENETICS; CARCINOGENESIS; CARDIAC IMAGING; CARDIOTOXICITY; CLEAR CELL CARCINOMA; DIAGNOSTIC IMAGING; GASTROINTESTINAL STROMAL TUMOR; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; DNA MUTATIONAL ANALYSIS; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; GENOME, HUMAN; HEART; HUMANS; METABOLOMICS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84872340132     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.05.066     Document Type: Review

References (55)

1. C.A. Dasanu, P. Padmanabhan, B.A. Clark 3rd, C. Do Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use Expert Opin Drug Saf 11 2012 445 457
2. S. Ederhy, H. Izzedine, C. Massard Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists Crit Rev Oncol Hematol 80 2011 369 379
3. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
4. T. Force, K.L. Kolaja Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10 2011 111 126
5. O. Fedorov, S. Muller, S. Knapp The (un)targeted cancer kinome Nat Chem Biol 6 2010 166 169
6. T. Eschenhagen, T. Force, M.S. Ewer Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
7. D. Cardinale, M. Salvatici, M.T. Sandri Review: role of biomarkers in cardioncology Clin Chem Lab Med 49 2011 1937 1948
8. R. Kerkela, L. Grazette, R. Yacobi Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916
9. T.F. Chu, M.A. Rupnick, R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
10. R.M. Steingart, G.L. Bakris, H.X. Chen Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors Am Heart J 163 2012 156 163
11. M.L. Maitland, G.L. Bakris, H.R. Black Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
12. M.R. Stratton Exploring the genomes of cancer cells: progress and promise Science 331 2011 1553 1558
13. F. Di Nicolantonio, A. Bardelli Kinase mutations in cancer: chinks in the enemy's armour? Curr Opin Oncol 18 2006 69 76
14. K.M. Wong, T.J. Hudson, J.D. McPherson Unraveling the genetics of cancer: genome sequencing and beyond Annu Rev Genomics Hum Genet 12 2011 407 430
15. P.C. Nowell, D.A. Hungerford Chromosome studies on normal and leukemic human leukocytes J Natl Cancer Inst 25 1960 85 109
16. D. Stehelin, H.E. Varmus, J.M. Bishop, P.K. Vogt DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA Nature 260 1976 170 173
17. A. Torkamani, G. Verkhivker, N.J. Schork Cancer driver mutations in protein kinase genes Cancer Lett 281 2009 117 127
18. T.G. Krontiris, G.M. Cooper Transforming activity of human tumor DNAs Proc Natl Acad Sci U S A 78 1981 1181 1184
19. C. Shih, L.C. Padhy, M. Murray, R.A. Weinberg Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts Nature 290 1981 261 264
20. C. Greenman, P. Stephens, R. Smith Patterns of somatic mutation in human cancer genomes Nature 446 2007 153 158
21. L.E. Macconaill, L.A. Garraway Clinical implications of the cancer genome J Clin Oncol 28 2010 5219 5228
22. L. Chin, J.W. Gray Translating insights from the cancer genome into clinical practice Nature 452 2008 553 563
23. L. Chin, W.C. Hahn, G. Getz, M. Meyerson Making sense of cancer genomic data Genes Dev 25 2011 534 555
24. S.A. Forbes, G. Bhamra, S. Bamford The Catalogue of Somatic Mutations in Cancer (COSMIC) Curr Protoc Hum Genet 2008 Chapter 10:Unit 10.11
25. L.D. Wood, D.W. Parsons, S. Jones The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113
26. P.M. Lizardi, M. Forloni, N. Wajapeyee Genome-wide approaches for cancer gene discovery Trends Biotechnol 29 2011 558 568
27. M. Meyerson, S. Gabriel, G. Getz Advances in understanding cancer genomes through second-generation sequencing Nat Rev Genet 11 2010 685 696
28. L. Sastre New DNA sequencing technologies open a promising era for cancer research and treatment Clin Transl Oncol 13 2011 301 306
29. M.S. Collett, R.L. Erikson Protein kinase activity associated with the avian sarcoma virus src gene product Proc Natl Acad Sci U S A 75 1978 2021 2024
30. A.D. Levinson, H. Oppermann, L. Levintow, H.E. Varmus, J.M. Bishop Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein Cell 15 1978 561 572
31. S.J. Heidorn, C. Milagre, S. Whittaker Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
32. J. Zhang, P.L. Yang, N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39
33. B. Nolen, S. Taylor, G. Ghosh Regulation of protein kinases; controlling activity through activation segment conformation Mol Cell 15 2004 661 675
34. C.J. Richardson, Q. Gao, C. Mitsopoulous, M. Zvelebil, L.H. Pearl, F.M. Pearl MoKCa database - mutations of kinases in cancer Nucleic Acids Res 37 2009 D824 D831
35. K. Kasaian, S.J. Jones A new frontier in personalized cancer therapy: mapping molecular changes Future Oncol 7 2011 873 894
36. D. Fabbro, S.W. Cowan-Jacob, H. Mobitz, G. Martiny-Baron Targeting cancer with small-molecular-weight kinase inhibitors Methods Mol Biol 795 2012 1 34
37. M.H. Chen, R. Kerkela, T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
38. H. Cheng, T. Force Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics Circ Res 106 2010 21 34
39. Z.A. Knight, H. Lin, K.M. Shokat Targeting the cancer kinome through polypharmacology Nat Rev Cancer 10 2010 130 137
40. J. Zhang, F.J. Adrian, W. Jahnke Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
41. L. Garuti, M. Roberti, G. Bottegoni Irreversible protein kinase inhibitors Curr Med Chem 18 2011 2981 2994
42. O. Yamaguchi, T. Watanabe, K. Nishida Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis J Clin Invest 114 2004 937 943
43. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
44. A. Fernandez, A. Sanguino, Z. Peng An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic J Clin Invest 117 2007 4044 4054
45. B.B. Hasinoff The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity Toxicol Appl Pharmacol 244 2010 190 195
46. G. Minotti, E. Salvatorelli, P. Menna Pharmacological foundations of cardio-oncology J Pharmacol Exp Ther 334 2010 2 8
47. K.J. French, R.W. Coatney, J.P. Renninger Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity Toxicol Pathol 38 2010 691 702
48. H. Cheng, G. Kari, A.P. Dicker, U. Rodeck, W.J. Koch, T. Force A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity Circ Res 109 2011 1401 1409
49. B.D. Anson, K.L. Kolaja, T.J. Kamp Opportunities for use of human iPS cells in predictive toxicology Clin Pharmacol Ther 89 2011 754 758
50. J.E. Babiarz, M. Ravon, S. Sridhar Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling Stem Cells Dev 21 2012 1956 1965
51. M. Pekkanen-Mattila, H. Chapman, E. Kerkela Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype Exp Biol Med (Maywood) 235 2010 522 530
52. J.D. Cohen, J.E. Babiarz, R.M. Abrams Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations Toxicol Appl Pharmacol 257 2011 74 83
53. Z. Lin, Y. Will Evaluation of drugs with specific organ toxicities in organ-specific cell lines Toxicol Sci 126 2012 114 127
54. R.E. Gerszten, A. Asnani, S.A. Carr Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics Circ Res 109 2011 463 474
55. H. Sawaya, I.A. Sebag, J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380